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Objectives The purpose of this study was to assess the utility of dobutamine cardiovascular magnetic resonance (DCMR)
results for predicting cardiac events in individuals with reduced left ventricular ejection fraction (LVEF).
Background It is unknown whether DCMR results identify a poor cardiac prognosis when the resting LVEF is moderately to
severely reduced.
Methods Two hundred consecutive patients ages 30 to 88 (average 64) years with an LVEF 55% that were poorly
suited for stress echocardiography underwent DCMR in which left ventricular wall motion score index
(WMSI), defined as the average wall motion of the number of segments scored, was assessed at rest, dur-
ing low-dose, and after peak intravenous infusion of dobutamine/atropine. All participants were followed
for an average of 5 years after DCMR to ascertain the post-testing occurrence of cardiac death, myocardial
infarction (MI), and unstable angina or congestive heart failure warranting hospital stay.
Results After accounting for risk factors associated with coronary arteriosclerosis and MI, a stress-induced increase in
WMSI during DCMR was associated with future cardiac events (p  0.001). A DCMR stress-induced change in
WMSI added significantly to predicting future cardiac events (p  0.003), after accounting for resting LVEF, but
this predictive value was confined primarily to those with an LVEF 40%.
Conclusions In individuals with mild to moderate reductions in LVEF (40% to 55%), dobutamine-induced increases in WMSI fore-
cast MI and cardiac death to a greater extent than an assessment of resting LVEF. In those with an LVEF40%, a
dobutamine-induced increase in WMSI does not predict MI and cardiac death beyond the assessment of resting
LVEF. (J Am Coll Cardiol 2008;52:279–86) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.025s
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pobutamine cardiovascular magnetic resonance (DCMR)
xhibits high clinical utility for identifying myocardial isch-
mia in patients with chest pain suspected to have flow-
imiting epicardial coronary arterial narrowings (1,2). This
oninvasive stress imaging modality exhibits low interob-
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008, accepted April 14, 2008.erver variability for the interpretation of left ventricular
LV) stress-induced wall motion abnormalities (WMA) (3),
nd in patients with a resting left ventricular ejection
raction (LVEF) 40%, DCMR stress-induced WMA
erve as additive, independent predictors of future myocar-
ial infarction (MI) and cardiac death (4). At present,
owever, the prognostic utility of DCMR stress-induced
V WMA in patients with an LVEF 40% at rest has not
een determined. This question is important to address,
ecause many patients presenting for cardiovascular care
xhibit a moderately to severely reduced LVEF due to
re-existing coronary arteriosclerosis (5,6), or they exhibit
oor image quality during other forms of noninvasive
esting (2,7). This study was performed to determine the
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DCMR in Low LVEF July 22, 2008:279–86prognostic utility of DCMR
stress-induced LV WMA in pa-
tients with resting LV dysfunc-
tion who were poorly suited for
dobutamine stress transthoracic
echocardiography.
Methods
Study population. The study
was approved by the Institu-
tional Review Board at the
Wake Forest University School
of Medicine, and all partici-
pants provided informed con-
sent. Patients with contraindi-
cations to DCMR (implanted
pacemakers or defibrillators or
intracranial metal) or to receiving
dobutamine or atropine were ex-
luded from enrollment. From 1997 to 2004, 300 patients
nderwent DCMR to diagnose inducible ischemia with an
VEF 55%, resting segmental WMA, and 6 LV
yocardial segments not visualized during second harmonic
tress echocardiography with or without microbubble contrast.
To be eligible for inclusion in this study, a patient had to
uccessfully complete the low (7.5 g/kg/min) and high
oses of dobutamine and atropine (administered to achieve
0% of the maximum predicted heart rate response for age)
nd must not have experienced a coronary arterial revascu-
arization procedure within 45 days of the DCMR. Of 300
atients referred, 31 did not receive intravenous dobut-
mine/atropine due to the following: dissection or aneurysm
f the aorta (n  3), newly diagnosed large LV mobile
hrombus (n  11), new valvular vegetation due to endo-
arditis (n  1), severe ventricular ectopy preventing ade-
uate gating (n  3), inability to understand the instruc-
ions associated with the examination (n  2), newly
iagnosed severe hypertension (n  2), inability to lie flat
ecause of decompensated congestive heart failure (CHF)
n  2), anxiety (n  5), metal artifacts associated with
rior surgical procedures (n  1), or newly diagnosed
ongenital heart disease (n  1). Two hundred sixty-nine
ubjects received dobutamine, with 229 receiving both a low
7.5 g/kg/min) and high (40 to 50 g/kg/min) dose. This
atter high dose of dobutamine was not completed in 40
atients because of ventricular ectopy, an atrial arrhythmia,
r an early inducible LV wall motion abnormality with the
ow-dose infusion. Immediately after the test results were
btained, 29 individuals were referred for coronary artery
evascularization within 45 days. As a result, 200 subjects
ormed the study population. Of these, 80 participants were
lso included in the 2-year follow-up of a population
reviously reported from our group (4). Comprehensive
emographic data regarding health status and medication
Abbreviations
and Acronyms
CHF  congestive heart
failure
DCMR  dobutamine
cardiovascular magnetic
resonance
HR  hazard ratio
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
UA  unstable angina
WMA  wall motion
abnormalities
WMSI  wall motion score
indexse were collected at the time of testing. For the purposes of tata collection, prior MI, hypertension, diabetes, and hy-
ercholesterolemia were defined according to previously
ublished criteria (4).
obutamine/atropine imaging protocol. Images were ac-
uired according to previously published techniques (2,4)
ither with a 1.5-T GE Horizon or a 1.5-T GE CV/I
General Electric Medical Systems, Waukesha, Wisconsin)
hole body imaging system with a phased array cardiac
urface coil placed on the chest. Single-slice, multiphase
radient-echo images were acquired throughout testing.
atients’ routine use of medications, including beta-receptor
ntagonists, was not altered before testing.
mage analyses. Images were analyzed with a software
rogram designed for display of dobutamine stress magnetic
esonance images in a multi-window synchronized format
2,4). For each of the 17 segments at each of the 3 stages of
he protocol (rest, low-dose, and peak infusion), LV wall
otion was assessed with a visual scoring system in which
 normal, 2  hypokinetic, 3  akinetic, and 4 
yskinetic. Wall motion score index (WMSI) during each
tage of the protocol was defined as the cumulative sum of
ndividual segment scores divided by the number of inter-
reted segments. The change in WMSI from rest to
ow-dose and from low-dose to high-dose pharmacologic
nfusion was recorded.
ollow-up. Personnel unaware of the study design or
tress-testing results contacted each subject (or, if deceased,
n immediate family member). Any change in physical
tate, medical condition, or medication use was confirmed
y review of the participant’s medical records. Hard events
ere defined as MI (angina of30 min duration, and either
2 mm ST-segment elevation in 2 consecutive electrocar-
iogram leads or a rise in serum troponin I or creatine kinase
evel and its MB fraction 2 times the upper limit of normal)
8) or cardiac death (death in the presence of acute coronary
yndrome, significant cardiac arrhythmia, or refractory
HF) (9). The designation “any events” included hard events
long with unstable angina (UA) or CHF warranting hospital
dmission (4). When available, electrocardiogram, enzymatic,
r autopsy data were used to substantiate cardiac mortality. In
he case of 2 simultaneous cardiac events, the worst event
cardiac death  MI  UA  CHF) was selected for the
urpose of analyses. Time to any event was defined as time
o first event. Median follow-up time was calculated accord-
ng to the method proposed by Schemper and Smith (10).
tatistical analysis. All grouped data were expressed as
ean SD. Chi-square and Kruskal-Wallis tests were used
o assess differences in categorical and continuous charac-
eristics, respectively, between those with and without any
vents and between those with and without hard events.
aplan-Meier methods were used to estimate the probabil-
ty of cardiac events as a function of follow-up duration, and
og-rank tests were used to assess unadjusted differences
etween groups. Cox proportional hazards regression mod-
ls were used to identify independent predictors of the time
o cardiac events. The risk of a given variable was expressed
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July 22, 2008:279–86 DCMR in Low LVEFy a hazard ratio (HR) with corresponding 95% confidence
ntervals. Variables were considered significant if the null
ypothesis of no contribution could be rejected at a 2-sided
robability value of 0.05. Secondary analyses to calculate
he added benefit of stress-induced change in WMSI for
trata defined by the LVEF at rest were performed by Cox
roportional hazards models. Modeling that considered a
onlinear relationship between LVEF and the log of the
azard of having an event and nonlinear models estimating
ossible interactions between the effect of increased WMSI
nd LVEF were estimated with a Cox proportional model
hat allowed for spline fitting of continuous factors (S-Plus
.0 for Windows, Enterprise Developer, 2005 Insightful
orp., Seattle, Washington). The degrees of freedom for
he spline fits were chosen as the largest value that still
aused the risk of an event to be a monotonic decreasing
unction of LVEF.
esults
emographic data regarding all 200 participants are dis-
layed in Table 1. The majority (65%) of participants were
en. Eleven of the 200 subjects had atrial fibrillation at rest
nd throughout pharmacologic stress testing. The hemody-
amic data for the study participants are shown in Table 2.
ighty-three percent of participants reached 80% of the
aximum predicted heart rate response for age during
emographic Data
Table 1 Demographic Data
n  200 Yes (
Patient characteristics
Age, yrs 64 11 63
Men/women 130/70 6
Weight, kg 90 20 91
Height, cm 170 11 170
BSA, m2 2.06 0.67 2.01
LVEF, %*† 43.5 9 42
WMSI rest† 1.71 0.48 1.77
WMSI peak*† 1.59 0.50 1.68
Historical information, n (%)
Hypertension 145 (72) 8
Diabetes mellitus 80 (40) 4
COPD 40 (20) 2
Smoking 89 (44) 4
Hypercholesterolemia 114 (57) 6
Prior revascularization (CABG or PTCA) 114 (57) 5
Prior Q-wave MI 82 (41) 4
Medications, n (%)
Beta-blockers 96 (48) 5
Calcium antagonist 48 (24) 2
ASA 132 (66) 7
Nitrate 78 (39) 4
ACE inhibitor* 75 (37) 4
Diuretic* 102 (51) 6
p  0.05 any events yes versus no; †p  0.05 hard events yes versus no.
ACE angiotensin-converting enzyme; ASA acetylsalicylic acid; BMI bodymass index; BSA body s
VEF  left ventricular ejection fraction; MI  myocardial infarction; PTCA  percutaneous transluminaltress. Contact was made with all 200 participants at a
edian time of 60.6 months (interquartile range: 45.9 to
2.6 months).
Of the 140 patients whose WMSI decreased or stayed
nchanged from low-dose to peak dobutamine/atropine
nfusion, 63 (45%) experienced at least 1 cardiac event
including 19 [14%] with a hard event: 8 MIs and 11 cardiac
eaths). Of the 60 patients with an increase in WMSI from
ow dose to peak stress, 43 (72%) experienced at least 1
ardiac event during the 5 years of follow-up (including 16
27%] with a hard event).
As shown in Figures 1A and 1B, compared with those
ithout a cardiac event, participants experiencing a cardiac
vent exhibited a higher WMSI from low dose to peak
harmacologic stress; conversely, a decrease in WMSI from
est to low-dose dobutamine infusion occurred in partici-
ants without cardiac events. Participants experiencing a
ard event exhibited a higher WMSI at rest and peak stress
ompared with those without an event (p 0.0001 and p
.00001, respectively, as shown in Fig. 1B). As shown in
igure 2, an increase in WMSI induced by the infusion of
obutamine was associated with a reduced event-free sur-
ival for any event (p 0.0016) and approached significance
or hard events (p  0.0503).
Analysis performed in men and women separately dem-
nstrated a similar HR for both genders (Fig. 3) of any
Any Events Hard Events
06) No (n  94) Yes (n  35) No (n  165)
65 11 63 10 64 11
62/32 26/9 104/61
90 19 90 20 91 20
171 11 170 11 170 11
4 2.12 0.99 2.01 0.25 2.07 0.7
45 9 39 10 44 9
1 1.64 0.45 2.01 0.50 1.65 0.46
3 1.49 0.45 1.94 0.52 1.52 0.47
65 (69) 24 (69) 121 (73)
33 (35) 16 (46) 64 (39)
17 (18) 7 (21) 33 (20)
41 (44) 16 (46) 73 (44)
54 (57) 17 (49) 97 (59)
55 (59) 19 (54 95 (58)
40 (43) 18 (51) 64 (39)
42 (45) 15 (43) 81 (49)
19 (20) 8 (23) 40 (24)
61 (65) 20 (57) 112 (68)
35 (37) 14 (40) 64 (39)
26 (28) 16 (46) 59 (36)
38 (40) 23 (66) 79 (48)n  1
 11
8/38
 21
 10
 0.2
 10
 0.5
 0.5
0 (75)
7 (44)
3 (22)
8 (45)
0 (57)
9 (56)
2 (40)
4 (51)
9 (27)
1 (67)
3 (41)
9 (46)
4 (60)urface area; CABG coronary artery bypass graft; COPD chronic obstructive pulmonary disease;
coronary angioplasty; WMSI  wall motion score index.
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DCMR in Low LVEF July 22, 2008:279–86vents, but the p value for statistical significance was
ifferent due to the smaller number of women studied (men
R: 1.93, p  0.008; and women HR: 1.64, p  0.1503).
hese trends were not different from one another (p 
.64). Historical information was assessed to identify risk
actors for coronary arteriosclerosis and MI. After account-
ng for risk factors for coronary arteriosclerosis and MI in a
ultivariate model (Fig. 4), an increase in WMSI from low
o peak dobutamine/atropine dose was the only independent
redictor of cardiac events (HR: 1.7, p  0.008).
obutamine Stress Data
Table 2 Dobutamine Stress Data
Hemodynamic Measures n  200 Yes
Rest heart rate (beats/min) 71 13
Peak heart rate (beats/min) 122 18 1
% maximum predicted HR adjusted for age* 92 14
Rest systolic blood pressure (mm Hg) 138 22 1
Peak systolic blood pressure (mm Hg) 144 27 1
Rest diastolic blood pressure (mm Hg) 77 13
Peak diastolic blood pressure (mm Hg) 74 15
Rate pressure product rest 9,863 2,390 9,9
Rate pressure product stress 17,531 4,283 17,2
alues expressed as mean  SD. *p  0.05, any events yes versus no.
Figure 1 Predictive Value of Stress-Induced Change in WMSI fo
Panel A demonstrates the wall motion score index (WMSI) (y-axis) during the 3 ph
each stage, the mean  SE of the estimate is shown. As noted, for any events, th
any events (A). As shown in panel B, the resting and peak WMSI was higher in pa
magnetic resonance; DBT  dobutamine.To determine whether the risk predicted by an increase in
MSI was consistent for the range of LVEF studied (18%
o 55%), we fit nonlinear spline functions to predict the risk
f hard and any cardiac events for those with and without an
ncrease in WMSI (Figs. 5A and 5B). For individuals with
n increase in WMSI and a rest LVEF 40%, the HR for
xperiencing a hard event was 3.09 (p  0.017) and for
xperiencing any event was 2.20 (p  0.0015). Ninety-one
ercent of those with an LVEF 40% but without an
ncrease in WMSI during dobutamine were hard-event free
Any Events Hard Events
106) No (n  94) Yes (n  35) No (n  165)
14 70 12 73 12 71 13
18 122 19 125 14 121 19
14 93 15 94 11 92 15
24 138 21 135 25 139 21
28 147 27 141 27 145 27
14 77 12 75 16 78 12
14 75 15 75 14 74 15
2,581 9,719 2,171 9,921 2,289 9,851 2,418
4,559 17,860 3,964 17,625 4,386 17,512 4,276
rd and Any Events
f dobutamine infusion (rest, low-dose infusion, and after peak stress). Within
rence in WMSI from low dose to peak stress was higher in those experiencing
experiencing myocardial infarction and cardiac death. CMR  cardiovascular(n 
72
21
91
39
42
77
73
97
25r Ha
ases o
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July 22, 2008:279–86 DCMR in Low LVEFt 5 years. For patients with an LVEF 40%, the relative
isk for experiencing a hard event was high with or without
n increase in WMSI during dobutamine (HR: 3.64 [68%
ard-event free at 5 years] and HR: 2.84 [70% hard-event
ree at 5 years], respectively) and was similar to the increased
isk of those with an LVEF 40% that experienced an
ncrease in WMSI with stress (HR: 3.09). For a hard event,
he HR for subjects who increased their WMSI (Fig. 4) or
hat exhibited an LVEF 40% at rest (HR: 3.01, p 
.0031) was high.
Overall, an increase in WMSI predicted an increased risk
f any events (HR: 1.85, p  0.002). Figure 5B illustrates
Figure 2 Event-Free Survival After Dobutamine Stress
Kaplan-Meier event-free survival curves in patients with resting left ventricular dysf
during dobutamine cardiovascular magnetic resonance stress. Compared with pati
nificantly lower in patients with increased WMSI either for any event (p  0.002, A
Figure 3 Event-Free Survival by Gender
Kaplan-Meier any event-free survival curves in men and women with resting left ve
index (WMSI) during dobutamine cardiovascular magnetic resonance (DCMR) stres
lower event-free survival at 60 months (p  0.008 for men and p  0.15 for womhat an increase in WMSI was not associated with a
ignificant increase in the risk of any events in subjects with
n LVEF 40% (HR: 1.36, p  0.36), but there was a
arger increase in risk for subjects with LVEF 40% (HR:
.17, p  0.002).
We also performed analyses to determine whether the
ocation and distribution of myocardial segments responsi-
le for the increase in WMSI were associated with an
dverse cardiac prognosis. In these analyses, segments were
efined as adjacent or remote depending on whether seg-
ents with worsening contraction during dobutamine were
ontiguous or separate from one another in 3-dimensional
n who did or did not experience an increase in wall motion score index (WMSI)
ith no evidence of stress-induced increase of WMSI, event-free survival was sig-
r hard events (p  0.05, B).
r dysfunction who did or did not experience an increase in wall motion score
h men and women who experienced an increase in WMSI during DCMR had a
th a similar trend for both genders (p  0.64). HR  hazard ratio.unctio
ents w
) or fontricula
s. Bot
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DCMR in Low LVEF July 22, 2008:279–86pace. All but 1 participant with 5 myocardial segments
ith worsening wall motion during dobutamine exhibited at
east 1 myocardial segment that was remote from the others.
n participants with 2 to 4 segments developing an inducible
all motion abnormality during testing, those participants
ith segments located remote to one another experienced a
orse cardiac prognosis compared with those with segments
ocated adjacent to one another (p  0.04).
The results in this study address the prognostic significance
f the change in LV wall motion score averaged among the 17
egments assessed (WMSI). In a prior study (4), in individuals
ith an average LVEF of 58%, we demonstrated that a change
n LV wall motion score in any segment was associated with an
dverse cardiac prognosis (HR: 7.9, p 0.001). In the current
tudy of participants with an average LVEF of 44%, 53% of
ubjects exhibited a change in wall motion score in a single
egment, but this single segment change did not predict an
ncrease in the risk of hard events (HR: 1.20, p 0.59) or any
vents (HR: 1.17, p  0.43).
iscussion
reviously, our group reported the utility of DCMR-
nduced LV WMA for identifying those at risk for future
ardiac events, including MI and cardiac death (4). A
imitation of the prior work was that there were too few
atients with a resting LVEF 40% for determining the
Figure 4 Multivariate Determinants of Cardiac Events
Multivariate analyses displaying hazard ratios  95% confidence intervals
(x-axis) for developing myocardial infarction (MI) or cardiac death. This model
includes risk factors for coronary arteriosclerosis and MI. As shown, a stress-
induced increase of wall motion score index (WMSI) is an independent predic-
tor of MI and cardiac death after accounting for these variables. BMI  body
mass index; CMR  cardiovascular magnetic resonance; LVEF  left ventricu-
lar ejection fraction.tility of dobutamine-induced WMA to predict those atisk of future MI and cardiac death. The current study
ddresses this limitation by enrolling 200 individuals with
atisfactory examinations that exhibited a resting LVEF
anging from 18% to 55%. No participants were lost to
ollow-up, and all participants’ events were confirmed
hrough review of their medical records.
In the current study, in patients with an LVEF 55%,
esting and stress-induced changes in LV WMSI during
CMR were observed in participants with adverse cardiac
vents including MI and cardiac death (Figs. 1 and 2). In
ddition, the utility of the results for predicting adverse
vents was similar in men and women (Fig. 3), and DCMR
tress-induced changes in WMSI predicted future cardiac
vents independent of conventional risk factors for coronary
rteriosclerosis or MI (Fig. 4).
Figure 5 Relationship Between Cardiac Events and LVEF
Hazard ratio of experiencing a hard event (A) or any event (B) as a function of
left ventricular ejection fraction (EF). Each point represents an event experi-
enced by a study participant. The hazard values are relative to a patient with-
out a dobutamine-induced increase in wall motion score index (WMSI) and a
resting left ventricular EF  40%.
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July 22, 2008:279–86 DCMR in Low LVEFImportantly, however, the utility of an increment in
MSI during dobutamine for the purpose of forecasting
ardiac events depended on the resting LVEF. We found
hat, in patients with an LVEF 40%, an increase in
MSI during dobutamine forecasted a high future risk of
ardiac events that was similar to the risk experienced by
ndividuals with an LVEF 40% with or without an
ncrease in WMSI during DCMR. Subjects with an LVEF
40% but 55% that did not have an increase in WMSI
ncurred a small risk of a hard event (91% were hard-event
ree at 5 years). However, those with an LVEF 40% with
r without an increase in WMSI experienced a high risk of
ncurring a hard event within the next 5 years (only 68%
with an increase in WMSI] and 70% [without] were
ard-event free at 5 years). An increase in WMSI during
obutamine did not, after accounting for a resting LVEF of
40%, independently predict future MI and cardiac death.
ikewise, however, if the WMSI increased during dobut-
mine, an LVEF 40% did not predict future hard events.
As shown in Figure 5B, there was a trend toward the
tility of a dobutamine-induced change in WMSI for
redicting any adverse event across the range of LVEF
tudied. Most (67%) of the “any” events in our population
ncluded admission to the hospital with UA or CHF (often
ermed “soft” events). Because hard and soft events were
orrelated (and thus a hard event would preclude observa-
ion of a later soft event), we were unable to use the data
rom this study to determine whether a change in WMSI
uring dobutamine could serve as an independent predictor
f admission to the hospital with UA or CHF.
An increase in WMSI in remote or noncontiguous LV
all segments was associated with a higher incidence of
ardiac events compared with those individuals experiencing
nducible ischemia in adjacent or contiguous LV segments.
nadequate blood flow remote to regions of ischemia or
nfarction has been shown to be related to adverse LV
emodeling (11,12) and the presence of flow-limiting ste-
oses in multiple epicardial coronary arterial segments
often termed “multivessel coronary artery disease”) (13,14).
he results of this study indicate that it is important for
hose interpreting DCMR examinations to recognize the
resence of remote segmental ischemia during image inter-
retation, because its presence during DCMR confers an
dverse prognosis in patients with a reduced resting LVEF.
Women represent roughly 40% of those referred for
oninvasive stress testing (15). In this study, women repre-
ented 35% of the enrolled participants. As shown in Figure
, an increase in WMSI in women trended (p  0.10)
oward a reduced event-free survival, whereas in men, the
ncrease in WMSI was associated with a significantly (p 
.017) worse event-free survival. Statistically, the event-free
urvival curves for men and women with increased WMSI
ere not different (p  0.64). A study with 46% more
vents in women is needed to have adequate power to detect
he statistical significance of the observed effects in women. mWhen managing patients with a low LVEF, what con-
lusions from this and other studies should be drawn
egarding the use of dobutamine stress testing? First, the
ate of MI and cardiac death is high for patients referred for
obutamine stress that exhibit a low LVEF at rest. In this
tudy, the proportion of patients who experienced events
ver an average 5 years of follow-up without (45%) and with
72%) an increase in WMSI was similar to that reported in
revious studies (16,17) of stress echocardiography and
adionuclide scintigraphy (5-year event rates of 45% to 75%
or those with evidence of inducible ischemia during testing).
Second, rather than changes in single segments, it is the
ombined change of the average change in LV wall motion
cored across the left ventricle (WMSI) that is predictive of
vents. Interestingly, this finding is similar to the observa-
ions in the low-dose dobutamine echocardiography “viabil-
ty” published reports in which multiple (2) rather than
ingle LV segmental wall changes are needed to forecast
ecovery of LV wall motion after coronary artery revascu-
arization (18). Of note, the results of this study do not
efute prior dobutamine echocardiography and CMR results
ndicating that dobutamine-induced improvements in LV
all motion termed “contractile reserve” are useful for
redicting LV wall motion and contractility after successful
oronary artery revascularization (19).
Third, and perhaps most important, for those with
oderate to severe reductions in LVEF (in this study an
VEF 40%), observed increases in WMSI during dobut-
mine do not forecast MI and cardiac death to a greater
egree than the assessment of resting LVEF. Therefore,
igh-dose intravenous dobutamine might offer little utility
or predicting MI and cardiac death when the resting LVEF
s 40%. Perhaps other markers, such as abnormalities of
RI perfusion or delayed enhancement (that identify bor-
er zones of infarcts of high arrhythmogenic potential),
hould be sought to differentiate (or, because the cardiac risk
s high due to the rest LVEF, further select those at very
igh risk) those at the greatest risk of MI and cardiac death
20,21) in individuals with an LVEF 40%.
tudy limitations. We recognize the following limitations
o our study: first, we excluded participants from our final
nalysis who underwent revascularization within 6 weeks of
CMR. We sought to avoid the artificial introduction of
tudy events due to consequences of interventional proce-
ures performed on the basis of DCMR test results. We
ecognize, however, that individuals with ischemia who are
ot revascularized might reflect a higher-risk group. Sec-
nd, the majority of our subjects were Caucasian; thus the
pplication of the results of this study to individuals of other
ace and ethnic groups remains to be determined. Third,
his particular study incorporated a biplane apical measure-
ent of LVEF. Also, conventional gradient-echo rather
han steady-state free precession was used to gather the cine
hite blood images. Newer, faster steady-state free preces-
ion imaging techniques might enable the acquisition of
ore slices throughout the course of stress testing so that
m
L
s
w
r
(
t
i
C
I
(
f
a

p
r
R
C
v
S
w
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
286 Dall’Armellina et al. JACC Vol. 52, No. 4, 2008
DCMR in Low LVEF July 22, 2008:279–86ore accurate multislice Simpson’s Rule determinations of
V volumes could be assessed throughout the course of a
tress test (22). Fourth, we did not implement quantitative
all motion analysis techniques in our patients. Given the
ecent association of myocardial strain with cardiac events
23), it would be useful to understand the relative value of
hese techniques to dobutamine stress results in future
nvestigations.
onclusions
n individuals with mild to moderate reductions in LVEF
40% to 55%), dobutamine-induced increases in WMSI
orecast MI and cardiac death to a greater extent than an
ssessment of resting LVEF. In those with an LVEF
40%, a dobutamine-induced increase in WMSI does not
redict MI and cardiac death beyond the assessment of
esting LVEF.
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